After a slow 2024, dealmaking in the U.S. healthcare sector is picking up. Springworks has a market value of $3 billion.

We recently compiled a list of the 10 Best Dow Jones Dividend Stocks According to Wall Street Analysts. In this article, we ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Shares of Merck and Pfizer are way down from their previous peaks. Merck's lead drug, Keytruda, grew sales by 19% last year, but its era of patent-protected exclusivity is approaching its end.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

At close: 11 February at 7:30:06 pm GMT+1 ...

At close: 7 February at 3:56:17 pm GMT-5 ...

Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

In October, Merck took up an option on the personalised RNA-based cancer vaccine with an upfront payment of $250 million as part of a collaboration first agreed in 2016 and expanded in 2018.